RxDoctor Payments Data

Monica Mazda, MD

Neurology · Indianapolis, INNPI 1770718116

Payments from drug & device makers

$8,443in general payments, 2019–2025

Across 461 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$887
  • Biogen$811
  • Pfizer$417
  • Livanova USA, Inc.$367
  • Eisai Inc.$291
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$8,35899%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)70$1,182
Novartis62$887
Biogen35$811
Pfizer22$417
Livanova USA, Inc.26$367
Eisai Inc.13$291
UCB, Inc.11$286
Jazz Pharmaceuticals Inc.9$260
Argenx US, Inc.12$245
Neurocrine Biosciences, Inc.12$235
CSL Behring10$211
Lilly USA, LLC6$199
MDD US Operations, LLC5$191
Sanofi7$154
AstraZeneca(2 entities)7$142
EMD Serono, Inc.19$138
Tanabe Pharma America, Inc.7$136
Takeda Pharmaceuticals U.S.A., Inc.6$134
Amgen(2 entities)7$132
Sunovion Pharmaceuticals Inc.13$131
Genentech USA, Inc.8$123
Supernus Pharmaceuticals, Inc.9$116
Catalyst Pharmaceuticals, Inc.4$100
Acorda Therapeutics, Inc5$87
Teva Pharmaceuticals USA, Inc.6$81
Assertio Therapeutics, Inc.6$78
Johnson & Johnson2$77
Octapharma USA, Inc.3$72
Harmony Biosciences LLC4$69
Arbor Pharmaceuticals, Inc.1$65
Banner Life Sciences, LLC3$65
Neurelis, Inc.3$61
Greenwich Biosciences, Inc.4$60
Bristol Myers Squibb3$60
Amneal Pharmaceuticals LLC4$53
SK Life Science, Inc.3$49
Sumitomo Pharma America, Inc.2$49
E.r. Squibb & Sons, L.L.C.2$49
Abbott2$40
Vanda Pharmaceuticals Inc.1$40
Merck2$37
Biohaven Pharmaceuticals, Inc.2$36
Shire North American Group Inc2$36
Alnylam Pharmaceuticals Inc.2$31
Mallinckrodt Hospital Products Inc.1$29
Acadia Pharmaceuticals Inc2$28
Otsuka America Pharmaceutical, Inc.1$27
Almatica Pharma LLC2$25
Cala Health, Inc.1$24
Springworks Therapeutics, Inc.1$23
Aucta Pharmaceuticals, Inc.1$23
Upsher-smith Laboratories LLC1$22
Lundbeck LLC1$22
Tonix Medicines, Inc.1$22
Biohaven Pharmaceutical Holding Company Ltd.1$22
Axsome Therapeutics, Inc.1$18
Ultragenyx Pharmaceutical Inc.1$18
Nevro Corp.1$17
Adamas Pharmaceuticals, Inc.1$17
Xeris Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,443 in reported general payments places this provider in the 65th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$57,941
Medicare patients
215
Services billed
768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$316,467
Gamunex-CImmune Globul G/Gly/Iga Avg 4649$168,784
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$112,451
Nurtec OdtRimegepant Sulfate46$58,498
Aimovig AutoinjectorErenumab-Aooe45$49,141
Emgality PenGalcanezumab-Gnlm43$39,851
UbrelvyUbrogepant21$23,987
QuliptaAtogepant15$16,248
Emgality SyringeGalcanezumab-Gnlm13$8,685
RytaryCarbidopa/Levodopa12$6,312
Levetiracetam131$4,731
Pregabalin174$2,845
Lacosamide38$2,700
Pyridostigmine Bromide11$2,102
Gabapentin130$1,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$211$316,46712 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$134$112,45111 claims
PfizerNurtec Odt$417$58,49846 claims
AbbVieUbrelvy, Qulipta$1,182$40,23536 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$53$8,41523 claims
Upsher-smith Laboratories LLCTopiramate$22$39650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →